

CITATION REPORT

List of articles citing

Current Considerations on Characterization of Immune Response to Multi-Domain Biotherapeutics

DOI: 10.1007/s40259-019-00389-8
BioDrugs, 2020, 34, 39-54.

Source: <https://exaly.com/paper-pdf/75023742/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
11	Toward Drug-Like Multispecific Antibodies by Design. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	18
10	European Immunogenicity Platform 11th Open Scientific Symposium on immunogenicity of biopharmaceuticals. <i>Bioanalysis</i> , 2020 , 12, 1043-1048	2.1	1
9	10 European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals. <i>MABs</i> , 2020 , 12, 1725369	6.6	6
8	Novel bioanalytical method for the characterization of the immune response directed against a bispecific F(ab) fragment. <i>Bioanalysis</i> , 2020 , 12, 509-517	2.1	3
7	Characterization of robust immune responses to a bispecific antibody, a novel class of antibody therapeutics. <i>Bioanalysis</i> , 2021 , 13, 239-252	2.1	3
6	2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation (- Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays). <i>Bioanalysis</i> , 2021 , 13, 415-463.	2.1	8
5	Bioanalysis in the Age of New Drug Modalities. <i>AAPS Journal</i> , 2021 , 23, 64	3.7	3
4	Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology.. 2022 , 10,		3
3	2021 White Paper on Recent Issues in Bioanalysis: TAb/NAb, Viral Vector CDx, Shedding Assays; CRISPR/Cas9 & CAR-T Immunogenicity; PCR & Vaccine Assay Performance; ADA Assay Comparability & Cut Point Appropriateness[- Recommendations on Gene Therapy, Cell Therapy, Vaccine Assay Harmonization, and New Modalities Integrated Summary of	2.1	1
2	Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics. 2022 , 14, 2672		0
1	Functional Deimmunization of Botulinum Neurotoxin Protease Domain via Computationally Driven Library Design and Ultrahigh-Throughput Screening.		0